Mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, has shown efficacy in ulcerative colitis and was approved by the US Food and Drug Administration (FDA ...

Results showed 92.9% of mirikizumab-treated patients who were in clinical remission at 1 year maintained clinical remission at 2 years. Continuous treatment with mirikizumab was associated with ...

Eli Lilly has said it plans to file its anti-IL-23p19 antibody mirikizumab for approval as a treatment for Crohn’s disease next year after it hit all its targets in a phase 3 trial. The VIVID-1 ...

Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as it waits for the outcome of regulatory reviews in ...

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Omvoh (mirikizumab-mrkz) as a treatment for people ...